The Health and Human Services Notice of Benefit and Payment Parameters for 2019 aims to increase state flexibility, improve affordability, strengthen program integrity, empower consumers, promote stability and reduce unnecessary regulatory burdens imposed by the Patient Protection and Affordable Care Act.
The finalized 2019 Medicare Advantage plan rates will rise an average of 3.4 percent, with other changes being implemented as well.
A pilot study conducted by U.S. investigators observed improvements in cognitive and behavioral function in 14 children with autism spectrum disorder and evidence of immune dysfunction who were administered high-dose intravenous immune globulin (IVIG) treatment over a period of 30 weeks.
New guidance from the Centers for Medicare and Medicaid Services allows work requirements to be used as a basis for eligibility for certain Medicaid beneficiaries.
Grifols’ higher-potency rabies immune globulin (RIG), HyperRAB S/D, was made available to healthcare providers
FDA's Vaccines and Related Biological Products Advisory Committee chose the Northern Hemisphere’s 2018-19 influenza (flu) vaccine strains based on the World Health Organization’s recommendations.
Discontinuation of the product is due to the preference among healthcare professionals and patients for newer, more advanced immune globulin options.
This first-ever prospective economic analysis by Canadian investigators found that home-based subcutaneous immune globulin (SCIG) therapy was associated with significantly lower average total nondrug costs than hospital-based intravenous immune globulin (IVIG) therapy for patients with primary immunodeficiency disorders.
The U.S. Food and Drug Administration has approved Shire’s VONVENDI, a recombinant von Willebrand factor treatment for perioperative management of bleeding in adults 18 years and older with von Willebrand disease.
The U.S. Food and Drug Administration approved Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), the first biosimilar drug to treat cancer.
GlaxoSmithKline's Nucala (mepolizumab) has been approved by the U.S. Food and Drug Administration to treateosinophilic granulomatosis with polyangiitis (EGPA).
The Centers for Medicare and Medicaid Services (CMS) is providing new policy guidance to help states design demonstration projects that promote the objectives of the Medicaid program and are consistent with federal statutory requirements.